3 Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, India Glycols and ITC
- October 16, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
GSK Pharma Rs 2,538.90, P/E 40.20. India Glycols Rs 349.85, P/E 7.58. ITC Rs 261.50, P/E 15.77. Closing prices of 14 Oct 2026.
Quick Answer
Vaccine maker, renewable chemical and diversified FMCG stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines sold through a large doctor network, India Glycols in glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and ITC in cigarettes, packaged foods, personal care, paperboards, hotels and agri products. FY26 revenue growth was 1.8% at GSK Pharma, 11.5% at India Glycols and 4.4% at ITC. P/E stands at 40.20 for GSK Pharma (industry 37.59), 7.58 for India Glycols (industry 54.53) and 15.77 for ITC (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Vaccine maker, renewable chemical and diversified FMCG stocks give investors exposure to medicines, chemicals and consumer goods used every day. Volumes, pricing and margins decide how much of that demand turns into profit.
This list covers three vaccine maker, renewable chemical and diversified FMCG stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines sold through a large doctor network, India Glycols for glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and ITC for cigarettes, packaged foods, personal care, paperboards, hotels and agri products. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks?
Vaccine maker, renewable chemical and diversified FMCG stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three vaccine maker, renewable chemical and diversified FMCG stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals | 2,538.90 | 42,939 | 40.20 | 37.59 | 45.69% | 0.01 |
| India Glycols | 349.85 | 2,397 | 7.58 | 54.53 | 9.98% | 0.58 |
| ITC | 261.50 | 318,338 | 15.77 | 34.85 | 28.53% | 0.03 |
Among healthcare, chemicals and consumer stocks, GSK Pharma trades at a premium to the industry P/E, while India Glycols and ITC trade at a discount.
Why Do Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks Have a Strong Roadmap in India?
Vaccine maker, renewable chemical and diversified FMCG stocks have a strong roadmap in India because vaccination demand, ethanol blending and wider consumer brands keep adding volumes for these firms. Three drivers stand out.
- Vaccination demand: Doctors prescribe more vaccines and branded medicines.
- Renewable chemicals: Ethanol and bio-based chemicals gain policy support.
- Brand spread: Packaged foods and personal care reach more homes.
GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap
GSK Pharma’s roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.
Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.
Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P/E of 40.20 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 40.20 is a modest premium to the industry P/E of 37.59, so the next quarters’ growth is the figure to follow.
India Glycols: Green Chemicals and Ethanol Build the Next Leg
India Glycols’ roadmap rests on glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock, with ethanol blending and chemical demand supporting volumes.
Revenue grew from Rs 2,889.84 crore in FY22 to Rs 4,216.34 crore in FY26, a 45.9% rise, and FY26 revenue was 11.5% higher than FY25. FY26 net profit rose 26.8% to Rs 292.76 crore. In Q1 FY27, revenue grew 19.3% to Rs 2,988.82 crore, and net profit rose 32.2% to Rs 96.83 crore. Operating margin was 7.12% in FY26.
Debt to equity is 0.58 and return on equity is 9.98%. FY26 operating cash flow was Rs 769.16 crore against capital expenditure of Rs 823.48 crore. India Glycols paid a dividend of Rs 7.5 per share for FY26, a yield of 2.10%. At a P/E of 7.58 against an industry P/E of 54.53, the stock trades below its industry multiple.
What to watch: The P/E of 7.58 against an industry P/E of 54.53 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
ITC: Several Businesses Anchor the Roadmap
ITC’s roadmap rests on cigarettes, packaged foods, personal care, paperboards, hotels and agri products, with several businesses supporting steady cash flow.
Revenue grew from Rs 62,504.44 crore in FY22 to Rs 81,294.27 crore in FY26, a 30.1% rise, and FY26 revenue was 4.4% higher than FY25. FY26 net profit rose 4.9% to Rs 21,018.15 crore. Over four years, net profit rose from Rs 15,503.13 crore in FY22 to Rs 21,018.15 crore. In Q1 FY27, revenue grew 26.7% to Rs 30,179.01 crore. Operating margin was 33.18% in FY26.
Debt to equity is 0.03 and return on equity is 28.53%. FY26 operating cash flow was Rs 18,464.31 crore against capital expenditure of Rs 2,182.89 crore. At a P/E of 15.77 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 15.77 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks in India: GSK Pharma vs India Glycols vs ITC on Key Financials
Among the best vaccine maker, renewable chemical and diversified FMCG stocks in India, GSK Pharma leads on FY26 operating margin and return on equity; India Glycols leads on FY26 revenue growth and FY26 net profit growth; ITC leads on Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | GSK Pharma | India Glycols | ITC |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 3,967.03 | 4,216.34 | 81,294.27 |
| FY26 revenue growth | 1.8% | 11.5% | 4.4% |
| FY26 net profit (Rs Cr) | 1,035.98 | 292.76 | 21,018.15 |
| FY26 net profit growth | 11.7% | 26.8% | 4.9% |
| FY26 operating profit margin | 38.60% | 7.12% | 33.18% |
| Q1 FY27 revenue growth (YoY) | 15.7% | 19.3% | 26.7% |
| Return on equity | 45.69% | 9.98% | 28.53% |
| P/E ratio | 40.20 | 7.58 | 15.77 |
| Debt to equity | 0.01 | 0.58 | 0.03 |
| FY26 operating cash flow (Rs Cr) | 903.30 | 769.16 | 18,464.31 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen vaccine maker, renewable chemical and diversified FMCG stocks and shortlist vaccine maker, renewable chemical and diversified FMCG stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track GSK Pharma, India Glycols and ITC live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover medicines, renewable chemicals and a diversified consumer group. GSK Pharma leads on FY26 operating margin and return on equity; India Glycols leads on FY26 revenue growth and FY26 net profit growth; ITC leads on Q1 FY27 revenue growth.
Across vaccine maker, renewable chemical and diversified FMCG stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the vaccine maker, renewable chemical and diversified FMCG stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Vaccine Maker, Renewable Chemical and Diversified FMCG Stocks
Which are the best vaccine maker, renewable chemical and diversified FMCG stocks in India with a strong roadmap?
Ans. GlaxoSmithKline Pharmaceuticals, India Glycols and ITC stand out for their roadmaps in medicines, renewable chemicals and a diversified consumer group. FY26 revenue growth was 1.8% at GSK Pharma, 11.5% at India Glycols and 4.4% at ITC, and return on equity ranges from 9.98% to 45.69%.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?
Ans. GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P/E of 40.20 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of GSK Pharma, India Glycols and ITC?
Ans. The P/E ratio is 40.20 for GSK Pharma (industry 37.59), 7.58 for India Glycols (industry 54.53) and 15.77 for ITC (industry 34.85). Only GSK Pharma trades at or above the industry multiple.
Which of these vaccine maker, renewable chemical and diversified FMCG stocks has the highest return on equity?
Ans. GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by ITC at 28.53% and India Glycols at 9.98%.
What are the risks of investing in vaccine maker, renewable chemical and diversified FMCG stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did GSK Pharma, India Glycols and ITC perform in Q1 FY27?
Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. India Glycols reported revenue of Rs 2,988.82 crore, up 19.3% year on year, and net profit rose 32.2% to Rs 96.83 crore. ITC reported revenue of Rs 30,179.01 crore, up 26.7% year on year.
Do vaccine maker, renewable chemical and diversified FMCG stocks pay dividends?
Ans. GSK Pharma and India Glycols pay dividends. The dividend yield is 2.25% for GSK Pharma and 2.10% for India Glycols, based on dividends declared for FY26.
How can I invest in vaccine maker, renewable chemical and diversified FMCG stocks in India?
Ans. You can buy vaccine maker, renewable chemical and diversified FMCG stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
